Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease
Objective: Our goal is to develop small molecules which support and restore nigrostriatal dopamine neurons by activation of glial cell line-derived-neurotrophic factor (GDNF) receptors. Background:…Bilateral Putaminal AAV2-GDNF Delivery the Treatment of Advanced Parkinson’s Disease
Objective: To investigate the safety, tolerability, and early clinical efficacy of escalating doses of AAV2-GDNF delivered into the bilateral putamen of patients with advanced PD…Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.
Objective: Assesing the neurorestorative effect of GDNF. Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…Gene delivery of AAV2-neurturin for patients with Parkinson’s disease: A meta-analysis
Objective: The objectives of this meta-analysis are: 1) to investigate the efficacy of AAV2-neurturin gene delivery for patients with Parkinson's disease; 2) to compare AAV2-neurturin…Pathological findings from two Parkinson’s disease patients after intraputaminal GDNF infusion
Objective: To describe the postmortem findings from two patients who underwent intraputaminal infusion of glial-derived neurotrophic factor (GDNF). Background: GDNF has been shown to have…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.